Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

In a randomized trial of adults with obesity or overweight, Vanda Pharmaceuticals’ investigational NK-1 receptor antagonist ...

Inhibikase Therapeutics ( ($IKT) ) has provided an announcement. On November 20, 2025, Inhibikase Therapeutics announced plans to advance IKT-001 ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of a comprehensive peer-reviewed narrative review that consolidates pharmacologic, pharmacokinetic and more than a decade of ...

Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON, Nov. 17, 2025 ...

Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets.

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 ...

Vanda advances with strong Fanapt growth, late-stage catalysts, GLP-1 potential, higher investment and solid balance sheet ...

Scientists have directly measured the minuscule electron sharing that makes precious-metal catalysts so effective. Their new technique, IET, reveals how molecules bind and react on metal surfaces with ...

Further exploration needed to fully optimize the biosecurity tool for practical applications within commercial pig farms.

Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals ...